Shares of Orphazyme Rise 25% Premarket; Co on Sunday Announced Progress Made in Understanding Potential Resolution of Topics Outlined in Complete Response Letter from FDA, Including Need for Additional Data to Support NDA

by | Nov 1, 2021 | Uncategorized | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.